Computational modeling and biological validation of novel non-steroidal ligands for the cholesterol recognition/interaction amino acid consensus (CRAC) motif of the mitochondrial translocator protein (TSPO).
Mitochondria play a critical role in the physiological homeostasis of the cell, contributing to numerous cellular processes, including bioenergetics, metabolism and cell life and death. Owing to their keystone role, mitochondria have gained much attention as pharmacological targets. The outer mitochondrial integral membrane translocator protein (TSPO) has attracted a significant degree of pharmacological interest owing to its ability to bind a number of classes of drugs with high affinity and specificity. In addition to its well-characterized drug binding site, TSPO possess an additional high-affinity ligand binding site, originally identified for its ability to bind the lipid cholesterol, which was named the cholesterol recognition/interaction amino acid consensus (CRAC) motif. Previous investigations from our laboratory identified additional ligands targeted to TSPO's CRAC motif which are able to potently inhibit mitochondrial cholesterol transport and steroid biosynthesis, processes for which TSPO has been well-characterized. However, all of these compounds possessed the steroidal backbone common to cholesterol and steroid hormones. In our efforts to expand our understanding of TSPO's CRAC motif, we performed studies aimed at identifying non-steroidal ligands for this motif. Molecular modeling and in silico screening of large chemical libraries identified a panel of compounds which were subsequently screened for bioactivity in a number of steroidogenic model systems. These efforts identified a family of non-steroidal CRAC ligands able to potently inhibit steroidogenesis, and at higher concentrations, promote apoptosis. In addition, the best candidate in this family was able to suppress testosterone synthesis when administered to rats, indicating that this novel family of non-steroidal CRAC ligands may serve as prototypes for the development of drugs useful for treatment of diseases of steroid overproduction, such as Cushing's syndrome and steroidogenic cell tumors in humans and animals.
The Research Institute of the McGill University Health Centre and Department of Medicine, McGill University, Montreal, Quebec, Canada.
Andrew S
AS
Midzak
The Research Institute of the McGill University Health Centre and Department of Medicine, McGill University, Montreal, Quebec, Canada.
Nagaraju
N
Akula
The Research Institute of the McGill University Health Centre and Department of Medicine, McGill University, Montreal, Quebec, Canada.
Malena B
MB
Rone
The Research Institute of the McGill University Health Centre and Department of Medicine, McGill University, Montreal, Quebec, Canada; Departments of Biochemistry and Pharmacology & Therapeutics, McGill University, Montreal, Quebec, Canada. Electronic address: vassilios.papadopoulos@mcgill.ca.
Vassilios
V
Papadopoulos
D000596:Amino Acids / Q000378:metabolism*; D000818:Animals; D001665:Binding Sites; D001692:Biological Transport / Q000502:physiology; D002784:Cholesterol / Q000378:metabolism*; D032921:Consensus; D008024:Ligands; D051379:Mice; D008928:Mitochondria / Q000378:metabolism; D051336:Mitochondrial Membranes / Q000378:metabolism; D024101:Mitochondrial Proteins / Q000378:metabolism; D008958:Models, Molecular; D017434:Protein Structure, Tertiary; D021381:Protein Transport / Q000502:physiology; D051381:Rats; D013256:Steroids / Q000378:metabolism*
D000596:Amino Acids; D008024:Ligands; D024101:Mitochondrial Proteins; D013256:Steroids; D002784:Cholesterol
Apoptosis; CRAC; Cholesterol; Steroidogenesis; TSPO